Skip to content

Participation in Competing Strategies for Colorectal Cancer Screening - a Randomized Health Services Study Within the National Screening Program in Poland

Participation In Competing Strategies for COLorectal Cancer screenINg - a randOmized Health Services Study Within the National Screening Program in Poland(PICCOLINO)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03790475
Acronym
PICCOLINO
Enrollment
12298
Registered
2018-12-31
Start date
2018-08-25
Completion date
2019-12-31
Last updated
2018-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

Colorectal Cancer Screening

Brief summary

The PICCOLINO is a randomized health services study performed within the framework of the Polish Colonoscopy Screening Program (PCSP) in Poland. Within the study 12,298 eligible persons between 55 and 64 years of age will be drawn from the Population Registry and randomly assigned in a 1:1:1 ratio to receive an invitation to participate in one of the three screening strategies: (I) postal invitation to colonoscopy and a re-invitation to colonoscopy for initial non-responders, (II) postal invitation for screening using fecal immunochemical test (FIT) for non-responders and subjects refusing a colonoscopy, or (III) postal invitation offering a choice between FIT and colonoscopy. Colonoscopies will be performed in seven local centers participating in the study. FITs will be analyzed in the central laboratory. Subjects with positive FIT result will be recommended to undergo colonoscopy. The primary outcome is participation with CRC screening within 18 weeks after enrollment, defined as completion of colonoscopy, or completion of FIT along with colonoscopy for positive FIT result. Secondary outcome will be diagnostic yield for advanced neoplasia (CRC or advanced adenoma). The study has been approved by a local bioethics committee.

Interventions

OTHEROffering a choice for colorectal cancer screening

Persons randomized to the multiple options screening strategy group will receive a postal invitation offering a choice between FIT and colonoscopy.

OTHEROffering an alternative colorectal cancer screening method

Persons randomized to the sequential screening strategy group will receive a postal invitation to the colonoscopy followed by a postal invitation for screening using FIT for non-responders and subjects refusing colonoscopy.

Sponsors

Ministry of Health, Poland
CollaboratorOTHER_GOV
Centre of Postgraduate Medical Education
CollaboratorOTHER
Maria Sklodowska-Curie National Research Institute of Oncology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
55 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

Men and women aged 55 to 64 years residing in Poland and assigned to be invited to screening within the Polish Colonoscopy Screening Program .

Exclusion criteria

* information of a selected subject death informed by family, neighbors or post office that has not been included in the Personal Identity Number (PESEL) system. * addressees of letters that have been returned by the post office. * subjects requiring long-term care due to somatic, psychosocial reasons or with mental disability. * history of colorectal resection.

Design outcomes

Primary

MeasureTime frameDescription
Completion of the assigned screening strategy within 18 weeks of enrollmentWithin 18 weeks of enrollmentCompletion of the assigned screening strategy within 18 weeks of enrollment defined as: * current screening strategy: documented screening colonoscopy, * sequential and multiple options strategies: documented colonoscopy, or receipt of FIT containing stool specimen. A positive FIT result requires subsequent documented colonoscopy to qualify as completed.

Secondary

MeasureTime frameDescription
Diagnostic yield for CRC and advanced adenomasWithin 18 weeks of enrollmentAdvanced adenoma defined as adenoma \>1 cm in size, or with high-grade dysplasia, or with villous component (\>25%).

Countries

Poland

Contacts

Primary ContactMichal Filip Kaminski, MD, PhD
kaminski.mf@gmail.com+48 605438330
Backup ContactNastazja Dagny Pilonis, MD
nastazja@gmail.com+48 510291110

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026